Immunohistochemical staining with an antibody recognizing the C-terminal neoepitope of aggrecanase-cleaved aggrecan (NITEGE) revealed that the palovarotene-treated osteochondromas contained larger amounts of degraded aggrecan products than in the control group (Figure 3B vs. Figure 3E). This evidence concerns the gene ACAN and Osteochondroma.